Probiotic Therapeutics in Periodontal Disease Management

Periodontal disease arises from a complex interplay between pathogenic microorganisms and host immunity, leading to inflammation, tissue breakdown and eventual bone loss. Conventional therapies, such as scaling and root planing often supplemented by antiseptics or antibiotics, can reduce microbial burden but may promote antimicrobial resistance and disrupt beneficial commensals. Probiotic therapeutics offer a targeted strategy to rebalance the oral microbiome, inhibit keystone pathogens, modulate inflammatory responses and support tissue homeostasis. By delivering live beneficial bacteria or their components, probiotic interventions can compete with pathogenic species for adhesion sites, secrete antimicrobial substances, enhance mucosal barrier function and stimulate host immunoregulation. Clinical studies have reported improvements in bleeding on probing, pocket depth and plaque accumulation, while mechanistic investigations reveal induction of antimicrobial peptides and suppression of pro-inflammatory cytokines. Despite promising results, efficacy is highly strain-dependent and influenced by dosage, delivery vehicle and treatment duration. Standardisation of protocols and deeper understanding of host–microbe interactions are essential to translate probiotic approaches into routine periodontal care worldwide.

Research from Nature Portfolio

Orally administered Lactobacillus gasseri SBT2055 has been shown in preclinical models to prevent Porphyromonas gingivalis-induced periodontal destruction. Gastric delivery of this strain reduced alveolar bone loss and preserved periodontal ligament integrity following bacterial challenge. Systemic immunomodulation was evidenced by decreased local expression of tumour necrosis factor-α and interleukin-6, alongside elevated production of β-defensin peptides both in distant mucosal sites and within gingival tissues. These findings suggest a gut–oral immune axis whereby probiotic administration enhances innate defence mechanisms and curbs inflammation in the periodontium.

Probiotic Therapeutics in Periodontal Disease Management publication trend

The graph below shows the total number of articles in probiotic therapeutics in periodontal disease management across all publications each year (not limited to Nature Index journals).

Technical terms

Probiotic: Live microorganisms which, when administered in adequate amounts, confer a health benefit on the host.

Biofilm: A structured community of microorganisms enclosed within a self-produced polymeric matrix adherent to a surface.

Dysbiosis: A disruptive imbalance in the composition or function of a microbial community associated with disease.

Pathobiont: A resident microbe with potential to cause pathology under certain environmental or host-related conditions.

References

1. Antimicrobial potential of known and novel probiotics on in vitro periodontitis biofilms. npj Biofilms and Microbiomes (2023).
2. Screening of heat-killed lactic acid bacteria based on inhibitory activity against oral bacteria and effects of oral administration of heat-killed Ligilactobacillus salivarius CP3365 on periodontal health in healthy participants: a double-blinded, randomized, placebo-controlled trial. Journal of Oral Microbiology (2023).
3. Antigingivitis and Antiplaque Effects of Oral Probiotic Containing the Streptococcus salivarius M18 Strain: A Randomized Clinical Trial. Nutrients (2023).
4. Oral administration of Lactobacillus gasseri SBT2055 is effective in preventing Porphyromonas gingivalis-accelerated periodontal disease. Scientific Reports (2017).